

# ABSTRACT SUBMISSION GUIDELINES

## 1. General Information

### Submission Deadline

- Submission is only available online at <https://submission.summitmd.com/login.php?iid=52>
- Submission closes on **Friday, November 8, 2024, 11:59:59 PM KST(UTC +9)**. Please complete the submission before the deadline.

### ID/Password for Submission

- To submit an abstract, you must join [www.summitmd.com](http://www.summitmd.com) first. If you haven't signed up yet, please join summitMD before the submission.
- You are advised **NOT** to use a Hotmail account for your ID as it blocks emails from us. If you use a Hotmail account, you may not be able to receive important notifications including acceptance letters, invitations, and further information about the presentation.
- If you forgot your user ID (email address) or Password, click "Forgot Your Password?" to reset the password.

## 2. Title

- The title of the abstract should be within 300 characters.
- It should be concise and specific, containing no abbreviations and indicating the nature of the investigation.
- **Please capitalize your title in proper APA style before the submission.**  
*Convert your title [here](#) to APA style and manually revise afterward.*

*ex) A Challenging Case Report: Instant Coronary Intervention **in a Female Before** Kidney Transplant*

## 3. Author(s)

- The designation of a single presenter is required to complete a submission.
- First author, presenter and co-author(s) can be the same person.
- Each author's information must be provided for submission. **Be sure to proofread carefully** as the authors' information will be included in a JACC online supplement and on the official website.
- **Once you submit your abstract, a confirmation email will be sent to you (submitter). If your abstract is accepted, the designated presenter will receive further notification emails for the presentation, and the submitter will receive emails for the JACC issue; Make sure all the contact information is correct.**

## 4. Categories

- Abstracts should involve the following disciplines in cardiovascular medicine and intervention.
- Select one category that is closest to the subject of your abstract.
- If the category does not match the subject of the abstract, you may receive a low score from the reviewers.

### CORONARY

ACS/AMI

Complex PCI

- Calcified Lesion
- Long Lesion
- Tandem Lesion
- CTO
- Multi-Vessel Disease
- Small Vessel Disease
- Left main
- Bifurcation
- In-Stent Restenosis

Imaging & Physiology

- FFR
- Invasive Imaging (IVUS, OCT, NIRS, VH, etc.)
- Non-Invasive Imaging (CTA, MRI, Echo, etc.)
- Angiography/QCA

High-Risk Intervention (Diabetes, Heart Failure, Renal Failure, Shock, etc.)

Vascular Access and Closure

Adjunctive Procedures (Thrombectomy, Atherectomy, Special Balloons)

Complication Management

DES/BRS/DCB

Hemodynamic Support  
Pharmacotherapy  
Surgical Therapy  
Clinical Trials & Science

## **STRUCTURAL**

### *Aorta Disease and Intervention*

- Bicuspid AV
- Minimalist TAVR
- Valve in Valve TAVR
- Antithrombotics
- Coronary Artery Protection / Access
- Complex TAVR
- Non-femoral TAVR

### *Mitral Valve Intervention*

- TEER
- Transcatheter MV Repair
- Transcatheter MV Replacement

### *Tricuspid Valve Intervention*

### *Imaging*

- Computed Tomography
- Echocardiography

### *Pulmonic Valve Intervention*

### *LAAO*

### *Surgical Therapy*

### *Other Structural Interventions*

## **ENDOVASCULAR**

### *Iliac / SFA Intervention*

### *Stroke and Neurovascular Interventions*

### *Thoracic & Abdominal Aortic Interventions*

### *Venous Disease Intervention*

### *Carotid Intervention*

### *Other Endovascular Intervention*

### *Thrombus Removal Devices and Techniques*

### *Surgical Therapy*

## **HEART FAILURE**

### *Vascular Heart Disease and Cardiomyopathies*

### *Cardiogenic Shock*

### *Mechanical Circulatory Support*

### *Pharmacotherapy*

### *Surgical Therapy*

## **INNOVATION**

### *Digital Health and Artificial intelligence*

### *Technology Trends in Coronary Intervention*

### *Technology Trends in Valve Intervention*

### *Pharmacotherapy*

### *Surgical Therapy*

## **5. Contents**

### **Basic info / Requirements**

- Abstracts must be submitted in English.
- Abstracts consist of 4 sections: Background, Methods, Results, and Conclusions.  
*Each section is required to contain min 150 char / Max 2200 char (approx. 300-350 words).*
- [Optional] In preparation for your possible publication in the JACC online supplement, please upload up to three images in each section.
- [Optional] To increase your chance of acceptance, you can upload videos separately, but they will be only accessible during review and won't be published.

### **Check Before You Submit**

- Abstracts may be entered directly into the site or copied and pasted, however, be sure to check again whether the special characters or symbols are not broken.

- You can copy and paste an existing Excel table or create a new table using the provided system tools, however, be sure to check again whether the special characters or symbols are not broken.
- Spaces are included.
- Use zeros before decimal points: 0.05, not .05
- Use decimal points, not commas: 0.05, not 0,05
- Use lowercase “p” values (p < 0.05).
- Provide a manufacturer name and location in parentheses for all brand or trade names.
- Never use the underline feature to denote the following symbols:  $\pm$ ,  $\leq$ ,  $\geq$ .
- Use space between numbers and symbols. (e.g., 3  $\pm$  4, not 3 $\pm$ 4; 3 mg, not 3mg).
- All measurements must include a unit of measure (e.g., systolic blood pressure "140 mmHg", not just "140").
- For brand drugs, include generic names in parentheses.
- Do not include references, credits, or grant support.

## 6. Review

- All submitted abstracts will be thoroughly evaluated by official reviewers, and the result will influence the allocation to two different types of sessions – *Best Clinical Trials Session* and *Abstract Presentation Session*.

## 7. Acceptance Notification

- The presenters of the accepted abstracts will be notified in mid-January 2025.
- After the notification, presenters will be informed of their presentation date and time with specific guidelines for the session.

## 8. Presentation

- Accepted abstracts will be allocated to a 1) *Best Clinical Trials Session* or 2) *Moderated Oral Abstract Competition* or 3) *E-Poster Presentation (Online Only)* based on the scores assigned by official reviewers.
- **All accepted abstracts will be published in the online supplement of the Journal of the American College of Cardiology (JACC).**

✂ *For every type of presentation, a presenter is required to submit a presentation slide.*

### Session Type

#### 1) Best Clinical Trials Session

- Abstracts containing novel findings that may improve current practices will be presented at this session.
- Studies that have been published before will be excluded.
- All the presenters in the Best Clinical Trials session will get a cash prize.
- Best Clinical Trials will be featured in *TCTAP's Daily News* and published in *an online supplement of 'The Journal of the American College of Cardiology (JACC)'*.

#### 2) Moderated Oral Abstract Competition

- This competition session will be led by prestigious moderators and panelists.
- The best presenter who gets the highest score from the moderators and panelists will get a cash prize.

#### 3) E-Poster Presentation (Online PPT Presentation: E-Science Station)

- Abstracts assigned to the E-Poster Presentation will be uploaded on E-Science Station, TCTAP website.
- Presenters won't present their abstract on-site, but a PPT file with audio will be posted online.

#### \* Benefits for All Presenters:

- An advantage in applying for the Best Young Scientist Award.
- **All selected abstracts will be published in an online supplement of the Journal of the American College of Cardiology (JACC).**
- Free attendance to TCTAP 2025.

## 9. Withdrawal

- Before December 1, 2024, you may log in and withdraw your submission.
- After December 1, 2024, please email [submission@cvrf.org](mailto:submission@cvrf.org) with your submission number and title to request a withdrawal.
- A withdrawal request must be made by March 9, 2025.

**10. No-Show policy**

When you cannot attend the session to present your case, please notify the secretariat in advance via email at [submission@cvmf.org](mailto:submission@cvmf.org). If the presenter fails to show up or sends a replacement without any notification, it may affect the acceptance of Call for Science in future conferences.

**11. Copyright Information**

When cases are submitted, we assume that the authors grant copyright to the Congress Organization for publication on the websites <https://www.summit-tctap.com/2025/> and [summitmd.com](http://summitmd.com). By submitting a case for the conference, the presenter verifies that the case's content and its conclusion should not have been published in any other meeting before our meeting.

**12. Assistance**

If you need help with your submission, please contact us at +82 2 3010 4799 or email [submission@cvmf.org](mailto:submission@cvmf.org).